Literature DB >> 30071553

Nontuberculous Mycobacteria in Cystic Fibrosis.

Brian S Furukawa1, Patrick A Flume2,3.   

Abstract

Nontuberculous mycobacteria (NTM) can cause chronic pulmonary infection in susceptible hosts. Individuals with cystic fibrosis (CF), a multisystem disease predominated by progressive structural lung disease, are particularly vulnerable. Only recently have NTM been recognized for their potential to cause lung deterioration in CF patients. The reported prevalence varies widely from 4 to 40%, significantly more common than in the general population, but this varies because of multiple factors including inconsistent screening practices. Mycobacterium abscessus complex and Mycobacterium avium complex are the two most common species recovered. Defining NTM pulmonary disease in a CF patient can present challenges as it can be difficult to distinguish from the other potentially pathogenic organisms in the lung microbiome. In general, treatment regimens do not differ from the non-CF population but the clinician should be aware of potential interactions with other CF therapies. Recent population-level genomics has raised serious concern for indirect person-to-person transmission of several dominating NTM clones worldwide, raising awareness for increase prevention strategies when CF patients potentially congregate, such as clinic visits. Lung transplantation is controversial in those with NTM present in sputum culture but the available evidence suggests that this is not an absolute contraindication. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2018        PMID: 30071553     DOI: 10.1055/s-0038-1651495

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  9 in total

Review 1.  Unmet needs in cystic fibrosis: the next steps in improving outcomes.

Authors:  Natalie E West; Patrick A Flume
Journal:  Expert Rev Respir Med       Date:  2018-06-19       Impact factor: 3.772

2.  Tissue-localized immune responses in people with cystic fibrosis and respiratory nontuberculous mycobacteria infection.

Authors:  Don Hayes; Rajni Kant Shukla; Yizi Cheng; Emrah Gecili; Marlena R Merling; Rhonda D Szczesniak; Assem G Ziady; Jason C Woods; Luanne Hall-Stoodley; Namal Pm Liyanage; Richard T Robinson
Journal:  JCI Insight       Date:  2022-06-22

Review 3.  Essential Topics for the Regulatory Consideration of Phages as Clinically Valuable Therapeutic Agents: A Perspective from Spain.

Authors:  Roberto Vázquez; Roberto Díez-Martínez; Pilar Domingo-Calap; Pedro García; Diana Gutiérrez; Maite Muniesa; María Ruiz-Ruigómez; Rafael Sanjuán; María Tomás; María Ángeles Tormo-Mas; Pilar García
Journal:  Microorganisms       Date:  2022-03-26

Review 4.  Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators.

Authors:  Samuel Estabrooks; Jeffrey L Brodsky
Journal:  Int J Mol Sci       Date:  2020-01-10       Impact factor: 5.923

Review 5.  Considerations for Phage Therapy Against Mycobacterium abscessus.

Authors:  Abrar Senhaji-Kacha; Jaime Esteban; Meritxell Garcia-Quintanilla
Journal:  Front Microbiol       Date:  2021-01-18       Impact factor: 5.640

6.  Mycobacterium abscessus biofilms have viscoelastic properties which may contribute to their recalcitrance in chronic pulmonary infections.

Authors:  Erin S Gloag; Daniel J Wozniak; Paul Stoodley; Luanne Hall-Stoodley
Journal:  Sci Rep       Date:  2021-03-03       Impact factor: 4.379

7.  Correlation between serum carbohydrate antigen 19-9 levels and computed tomography severity score in patients with nontuberculous mycobacterial pulmonary disease.

Authors:  Kangjoon Kim; Seung Hyun Yong; Su Hwan Lee; Sang Hoon Lee; Ah Young Leem; Song Yee Kim; Kyungsoo Chung; Eun Young Kim; Ji Ye Jung; Moo Suk Park; Young Sam Kim; Hye-Jeong Lee; Young Ae Kang
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

8.  Monoclonal antibodies from humans with Mycobacterium tuberculosis exposure or latent infection recognize distinct arabinomannan epitopes.

Authors:  Elise Ishida; Devin T Corrigan; Ryan J Malonis; Daniel Hofmann; Tingting Chen; Anita G Amin; Delphi Chatterjee; Maju Joe; Todd L Lowary; Jonathan R Lai; Jacqueline M Achkar
Journal:  Commun Biol       Date:  2021-10-12

9.  Performance of lipid fingerprint-based MALDI-ToF for the diagnosis of mycobacterial infections.

Authors:  Ximena Gonzalo; Agnieszka Broda; Francis Drobniewski; Gerald Larrouy-Maumus
Journal:  Clin Microbiol Infect       Date:  2020-08-27       Impact factor: 8.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.